CooperVision Inc delayed annual meeting June 22 May 14 allow board review recapitalization option meeting. CooperVision report quarter net income 64.6 mln dlrs 175.2 mln dlr pretax gain sale ophthalmic Johnson Johnson JNJ> 260 mln dlrs cash 17.9 mln dlr posttax charge debt repurchase. Sales 94.4 mln dlrs. A earlier earn 7300000 dlrs 120000 dlr loss discontinue operation sale 85.4 mln dlrs. The company aggressive investment spending maintain increase market share core business accelerate sale growth hold increase operating income near future. CooperVision "Furthermore entire net cash proceeds recent sale business employ reduce indebtedness strategic acquisition and/or otherwise employ relation recapitalization company recovery net income held loss particularly tax income (ophthalmic) pharmaceutical sell Johnson Johnson." Reuter 